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Abstract
Background: Multimorbidity and polypharmacy are very common in older adults in primary care. Ideally, general
practitioners (GPs), should regularly review medication lists to identify inappropriate medication(s) and, where
appropriate, deprescribe. However, it remains challenging to deprescribe given time constraints and few
recommendations from guidelines. Further, patient related barriers and enablers to deprescribing have to be
accounted for. The aim of this study was to identify barriers and enablers to deprescribing as reported by older
adults with polypharmacy and multimorbidity.
Methods: We conducted a survey among participants aged ≥70 years, with multimorbidity (≥3 chronic conditions)
and polypharmacy (≥5 chronic medications). We invited Swiss GPs, to recruit eligible patients who then completed
a paper-based survey on demographics, medications and chronic conditions. We used the revised Patients’
Attitudes Towards Deprescribing (rPATD) questionnaire and added twelve additional Likert scale questions and two
open-ended questions to assess barriers and enablers towards deprescribing, which we coded and categorized into
meaningful themes.
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Result: Sixty four Swiss GPs consented to recruit 5–6 patients each and returned 300 participant responses.
Participants were 79.1 years (SD 5.7), 47% female, 34% lived alone, and 86% managed their medications themselves.
Sixty-seven percent of participants took 5–9 regular medicines and 24% took ≥10 medicines. The majority of
participants (77%) were willing to deprescribe one or more of their medicines if their doctor said it was possible.
There was no association with sex, age or the number of medicines and willingness to deprescribe. After
adjustment for baseline characteristics, there was a strong positive association between willingness to deprescribe
and saying that because they have a good relationship with their GP, they would feel that deprescribing was safe
OR 11.3 (95% CI: 4.64–27.3) and agreeing that they would be willing to deprescribe if new studies showed an
avoidable risk OR 8.0 (95% CI 3.79–16.9). From the open questions, the most mentioned barriers towards
deprescribing were patients feeling well on their current medicines and being convinced that they need all their
medicines.
Conclusions: Most older adults with polypharmacy are willing to deprescribe. GPs may be able to increase
deprescribing by building trust with their patients and communicating evidence about the risks of medication use.
Keywords: Deprescribing, Polypharmacy, Multimorbidity, Patient attitudes, Older adults, General practice
Background
Managing patients with multimorbidity (≥3 chronic con-
ditions) has become the norm for general practitioners
(GPs). In the UK for example, three quarters of consul-
tations involve patients with multimorbidity [1]. Multi-
morbidity is strongly associated with age and with
polypharmacy (often defined as ≥5 chronic medicines
[2]). Currently, treatment guidelines are mainly based on
the management of single diseases and on evidence from
trials that often exclude older patients with multimor-
bidity [3] Therefore, recommendations for individual
medical conditions often fail to consider competing fac-
tors, such as drug-disease interactions and risks due to
polypharmacy [4]. As a result, the prevalence of poly-
pharmacy is on the rise, especially in patients with mul-
timorbidity. With this comes an increased risk for
potentially inappropriate medications (PIMs); these are
medications where the potential risk outweighs the po-
tential benefit in the individual. The possible conse-
quences of polypharmacy and PIMs use include
increased risk of adverse drug events [5], medicine errors
[6], adverse drug reactions [7], poor adherence [8], and
impaired quality of life [9], especially in older multimor-
bid patients [10].
Deprescribing is the withdrawal of PIMs with the goal
of managing polypharmacy and improving outcomes
[11]. Deprescribing is relevant and should be considered
for all patients who may be taking an inappropriate
medicine [12]. However, certain medications are often
targeted, such as high risk medicines in frail older adults,
preventive medicines in patients with limited life expect-
ancy [13] including people with cancer under palliative
care [14, 15].
While the rationale to deprescribe is clear, the imple-
mentation is less clear and in practice, important bar-
riers exist for physicians and patients [16]. Physicians
have reported that patient resistance or unwillingness to
deprescribe is a major barrier to deprescribing in prac-
tice [17]. Studies with patients have found that [18] fear,
lack of knowledge on how to deprescribe and belief that
their medicines are appropriate are barriers to their will-
ingness to have a medication deprescribed. Despite these
barriers, older adults have reported willingness towards
deprescribing when their health care professional is sup-
portive [19]. Barriers and enablers for deprescribing
might differ by countries, cultures and local health care
systems. Patient willingness to deprescribe has been pre-
viously studied in several countries, however, not all par-
ticipants had polypharmacy and multimorbidity and
were often not recruited from primary care [20–22] leav-
ing a gap in understanding the perspective of older pa-
tients with multimorbidity and polypharmacy in general
practice.
This study aims to determine the willingness towards
deprescribing in older adults with polypharmacy in
Switzerland, who are at high risk for potentially inappro-
priate medication and would therefore likely benefit
from deprescribing. We further wanted to learn which
potential barriers and enablers are most prevalent in this
population and to explore their association with the re-
ported willingness to deprescribe.
Methods
Design
Cross-sectional survey among patients in general prac-
tice using anonymous paper based questionnaires dis-
tributed by their GPs from May 2018 to February 2019.
Study population and processes
Inclusion criteria for patients were age 70 years or older,
multimorbidity (three or more chronic conditions), and
polypharmacy (regular intake of five or more chronic
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medicines). Furthermore, patients had to be able to read
and write in German language. There were no exclusion
criteria.
Patients were recruited by GPs. We invited Swiss GPs
to each recruit five to six eligible patients. Switzerland
has no registry of GPs which made it impossible to se-
lect a random sample. We therefore asked GPs who par-
ticipated in a former study using an online questionnaire
on attitudes of GPs towards deprescribing [23] if they
would assist in recruitment of patients. We also allowed
other GPs interested to participate through advertising
the study at Primary Care institutes and in GP quality
circles. All participating practices were paid 100 Swiss
Francs (about 100 Euros) to compensate for time re-
quired for screening, obtaining informed consent and
other recruitment related activities. The Ethics commit-
tee of the Canton of Bern approved the study. (Nr:
2017–02188).
Participating GPs were instructed to consecutively
screen for eligible patients during their regular consult-
ation program to limit selection bias. GPs recorded the
number of screened patients, number of eligible patients
and number of those not willing to participate.
All patients gave written informed consent to partici-
pate before receiving the paper-based study question-
naire. Patients were invited to answer the questionnaire
in the waiting room or at home anonymously and return
the survey to the medical assistant of their practices
(who then returned them as a batch to the study team).
Questionnaire
 We used the revised Patients’ Attitudes Towards
Deprescribing (rPATD) questionnaire for older
adults which contains twenty-two 5-point Likert
scale questions on attitudes and beliefs about their
medications and deprescribing. The rPATD was de-
veloped and validated in Australia [24] and has been
employed in various countries and settings [20, 21,
24]. The rPATD contains four factors with five
questions per factor (involvement, burden, appropri-
ateness, and concerns about stopping) as well as two
global questions. We translated the original ques-
tions from the rPATD from English into German.
This then underwent independent back-translation
from German to English by an individual who had
not seen the original English version. The translation
and back-translations were then reviewed by the re-
search team (including the primary author of the
original English rPATD, ER) with discussion and
editing of the German version to resolve any con-
cerns about the translation. As one of the aims of
the study was to quantify the barriers to and en-
ablers of deprescribing, 12 questions were added to
the questionnaire to cover topics important to pa-
tients in a primary care setting identified in previous
qualitative research [18]. These additional questions
were developed by members of the research team
(SS, NR, RKEP) and chosen for inclusion in the
study due to their perceived relevance to the local
context of primary care in the German speaking part
of Switzerland. The questions were not chosen ac-
cording to themes that were not represented in the
rPATD (as the factors of the rPATD are closely
aligned with the themes from this systematic re-
view), and instead were to broaden capturing of atti-
tudes within the themes. Where possible, the
wording of the question was kept as close to the
quotes from older adults in the original research
studies included in the systematic review, however,
wording was developed and refined by the research
team. The possible answers for all questions were:
strongly agree - agree – unsure – disagree – strongly
disagree.
 Two additional open-ended questions on other bar-
riers and enablers towards the willingness to depre-
scribing were also added to capture potential
barriers and enablers not included in the rPATD or
additional quantitative questions (“Do you think
there are other reasons why you wouldn’t reduce or
stop medicines?” and “Do you think there are other
reasons why you would like to reduce or stop medi-
cines?”). We then piloted the translated question-
naire and additional questions with four eligible
patients for comprehensibility (no changes were
required).
We also collected self-reported data:
 demographic data: age, sex, living status and
involvement in medication management.
 full list of current chronic medicines (intake of > 6
months). If participants had trouble self-completing
this list, they could seek help from their GP
 chronic conditions. We provided participants a list
of most prevalent chronic conditions in patient-
friendly language [25]. Participants could tick boxes,
if they were diagnosed with those diseases.
We used the STROBE statement checklist to report
our study findings [26].
Preliminary results of this project were presented at
the annual meeting of the European General Practice
Research Network in Tampere in May 2019 [27].
Statistical analysis
Our main outcome was willingness towards deprescrib-
ing, which was measured with the question from the
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rPATD: ‘If my doctor said it was possible, I would be
willing to stop one or more of my regular medicines’. If
participants answered, “strongly agree or agree” they
were considered to be willing to deprescribe.
We used descriptive statistics to report baseline char-
acteristics of our sample stratified by willingness to
deprescribe. To compare participants who were willing
to deprescribe versus not willing to deprescribe, we used
t-test and Chi2 test where appropriate. Likert-scale an-
swers from rPATD and the additional questions about
deprescribing were dichotomized from the 5-point
Likert scale responses into “strongly agree/agree” versus
“unsure/disagree/strongly disagree” for analysis. Differ-
ent members of the study team then separately catego-
rized them as enablers, barriers or involvement-related
and then discussed potential disagreement until agree-
ment was reached. These categories were formed for the
case if the question was answered with “strongly agree/
agree” (e.g. “I don’t like to take medicines”, if answered
with “strongly agree/agree” the statement qualifies as an
enabler towards deprescribing, but if answered with “un-
sure/disagree/strongly disagree” it is not necessarily a
barrier).
To adjust for baseline characteristics, we used a multi-
variable mixed-effects logistic regression model that also
accounted for possible clustering within each GP as a
random-effect. The same model was used to assess the
associations of items from the questionnaire and willing-
ness to deprescribe. In the model we adjusted a priori
for sex and age and for baseline characteristics if there
was a significant difference (p-value< 0.05) between
those willing and those not willing to deprescribe.
The first and last author analyzed the responses to the
open-ended questions. They coded and categorized an-
swers to the open questions (“Do you think there are
other reasons why you wouldn’t reduce or stop medi-
cines?” and “Do you think there are other reasons why
you would like to reduce or stop medicines?) into mean-
ingful themes. Disagreements were resolved by consen-
sus. After creating the list of themes, it was counted how
often the topics were mentioned by participants. Mul-
tiple answers were possible per participant.
A p-value < 0.05 was considered significant. Data man-
agement was done using EpiData Manager and EpiData
Entry Client v.4.4.1.0 (EpiData Association, Denmark).
Statistics were computed using Stata 15.02 (StataCorp,
College Station, TX, USA) for all analyses.
Results
We invited 830 Swiss GPs from all over the German part
of Switzerland to participate. Out of these, 64 (7.7%)
GPs recruited participants. Reasons why GPs did not
participate included lack of time, health issues or
personnel shortage in their practice. Participating GPs
and therefore their patients came from all over the Ger-
man speaking part of Switzerland.
Target recruitment was 5 to 6 patients per GP. During
the screening period, the 64 GPs screened 2537 consecu-
tive patients for eligibility, of those 531 (21%) met the in-
clusion criteria. Ultimately 300 participants were
included in this analysis. Reasons for non-participation
and a study flow chart is provided in Fig. 1.
Participant characteristics
Table 1 describes the baseline characteristics of our par-
ticipants: 47% were female, with a mean age of 79.1 years
(SD, 5.7). Thirty-four percent were living alone and 86%
managed their own medications. Twenty-nine percent
had no further or vocational education after obligatory
school; 49% had done an apprenticeship (vocational edu-
cation) and another 22% had higher education.
Participants had a mean number of 3.3 (SD 1.3)
chronic conditions from our list of common chronic
conditions in ambulatory care. The mean number of
medicines was 8.0 (SD 2.8) with the largest number of
medicines taken by a single participant being 22 medi-
cines. Twenty-four percent had excessive polypharmacy
[28], defined as taking 10 or more regular medicines.
The majority of our sample were willing to deprescribe
(77%). There was no significant differences in willingness
to deprescribe based on participant characteristics, ex-
cept for educational level. A greater proportion of partic-
ipants who were willing to deprescribe had higher
education compared to those who were not willing to
deprescribe (26% vs. 12%, p = 0.006).
Barriers and enablers towards deprescribing
Figure 2 describes results of the enablers, barriers and
other questions related to deprescribing. Among the en-
ablers, most participants reported that they had a good
relationship with their GP and therefore felt that depre-
scribing was safe (86%) and agreed that if new studies
found harm from taking too many medicines, they
would want to deprescribe (81%). Out of the 14 ques-
tions categorized as barriers, the majority agreed to 5 of
them. There was high satisfaction with current medica-
tions (97%) and most participants noticed an improve-
ment when taking their medicines (92%). Only 13% had
a previous bad experience with deprescribing. Partici-
pants showed a high involvement with their medicines:
97% wanted to know as much as possible about their
medicines; 95% stated to understand the reasons why
they were taking each of their medicines; 94% wanted to
be involved in decision making about their medicines;
89% always asked a healthcare professional if they had a
question about their medicines and 88% like to know as
much as possible about their medicines (Fig. 2).
Rozsnyai et al. BMC Geriatrics          (2020) 20:435 Page 4 of 11
Associations with willingness to deprescribe
In Table 2, we show the associations between baseline char-
acteristics and willingness to deprescribe with an adjusted
multilevel mixed-effects model. There was no significant as-
sociation between age, sex, number of medicines,
medication-self management, and living status with the
willingness to deprescribe. Participants with higher educa-
tion were more likely to be willing to deprescribe, com-
pared to those with basic education (p = 0.006).
Among our participants, 83 (28%) reported themselves
that they had less than three chronic conditions, despite
this being an inclusion criterion. As this likely indicates
a problem with how this data was collected (self-report
according to a pre-defined list), we did not use this vari-
able for analysis as intended a priori.
Figure 3 shows all the questions that had a statistically
significant association with willingness to deprescribe,
sorted by their strength of association. There was a
Fig. 1 Flow chart of study participants
Table 1 Baseline characteristics of study participants stratified by willingness to deprescribe
Baseline characteristics Overall
n = 300
Willing to deprescribea
n = 231 (77%)
Not willing to deprescribea
n = 69 (23%)
p-value
Female, n (%) (n = 300)b 141 (47) 104 (45) 37 (54) 0.21
Age, mean (SD)
(n = 292)
79.1 (5.7) 78.9 (5.7) 79.8 (5.8) 0.24
Living alone, n (%) (n = 298) 100 (34) 76 (33) 24 (35) 0.81
Self-management of medication, n (%) (n = 298) 256 (86) 196 (86) 60 (87) 0.78
Education level, n (%) (n = 299) 0.006
obligatory education 86 (29) 57 (25) 29 (42)
Apprenticeship 146 (49) 114 (49) 32 (46)
Higher education 67 (22) 59 (26) 8 (12)
Number of medicines, mean (SD) (n = 294) 8.0 (2.8) 8.0 (2.7) 8.1 (2.9) 0.89
5–9 medicines 228 (76) 176 (76) 52 (75)
≥ 10 medicines 72 (24) 52 (24) 13 (25) 0.89
SD standard deviation
aWilling to deprescribe, when answering true/rather true and not willing to deprescribe, when answering don’t know/rather not true/not true to the question: “If
my doctor said, it was possible I would be willing to stop one or more of my regular medicines’ “
bnumbers report the number of patients with no missing information on the respective variable
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Fig. 2 (See legend on next page.)
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strong positive association with participants belief that
they have a good relationship with their GP and so feel
safe about deprescribing (OR 11.3, 95%CI 4.6–27.0) and
that they would like to deprescribe if new studies found
harm from taking too many medicines (OR 8.0, 95%CI
3.8–16.9). Other enablers were, wanting their GP to re-
duce the dose of their medicines (OR 2.64, 95%CI 1.2–
5.8) and believing that they take too many medicines
(OR 2.5, 95%CI 1.2–5.5). Important barriers with a nega-
tive association to willingness to deprescribe were being
unsure about how to stop a medicine, even if their doc-
tor said that it is safe (OR 0.33, 95%CI 0.2–0.6) and pre-
viously having had a bad experience with deprescribing
(OR 0.4, 95%CI 0.2–0.8) (Fig. 3).
Open-ended questions
The highly mentioned barriers from the open ques-
tions were participants feeling well with their
current medicines and being convinced that they
need all of their medicines. Other barriers were
fear of recurrent symptoms or worsening of health.
The most commonly mentioned enablers were ex-
periencing a side effect or no effect from the medi-
cines, drug-drug interactions, trust in doctors to
only prescribe what is necessary and cost reduc-
tion (Table 3).
Discussion
Summary
In a consecutive sample of Swiss primary care patients,
21% were older than 70 years and had multimorbidity
and polypharmacy and were therefore eligible for inclu-
sion in our study. In our participants, who had a mean
age of 79.4 years and took an average of 8 regular medi-
cations, we found that most (77%) are willing to have a
medicine deprescribed if their doctor said it was pos-
sible. Individuals with a higher level of education were
more likely to be willing to deprescribe. Based on our re-
sults, the strongest enablers for patient willingness to
deprescribe are having a good relationship with their GP
and if new studies found harm from taking too many
medicines. Barriers were previously having a bad experi-
ence with deprescribing and uncertainties about how to
stop a medicine. Via our open questions, additional re-
ported barriers were being convinced that they need all
of their medicines and fear of recurrent symptoms.
While noticing side effects or no effects from their medi-
cines were reported enablers.
Comparison to existing literature
Our most important finding, that the majority of partici-
pants were willing to deprescribe, is consistent with find-
ings from other studies using the rPATD internationally
[19, 21, 22, 29, 30]. Our population was unique in
(See figure on previous page.)
Fig. 2 Enabler, barrier and involvement items, sorted by proportion of patients agreeing with questions per domain; Legend: Enabler, barrier and
involvement items from questionnaire, agreed or strongly agreed on (coloured part of the bar) versus unsure, disagreed, strongly disagreed on
(grey part of the bar) by patients with multimorbidity and polypharmacy. Items are sorted by proportion of patients agreeing with questions per
domain. * from rPATD
Table 2 Willingness to deprescribe, adjusted for patient characteristics and GP-clusters (n = 284)
Baseline characteristics Adjusted1 OR (95%CI) of participants willingness to deprescribe p-value1
Sex
Female 0.94 (0.49–1.79) 0.84
Male ref.
Age, per year increase 0.97 (0.92–1.02) 0.29
Living alone
Yes 1.27 (0.66–2.44) 0.47
No ref.
Self-management of medication
Yes 0.79 (0.33–1.92) 0.61
No
Education level
ref.
Obligatory education ref.
Apprenticeship 1.63 (0.84–3.16) 0.15
Higher education 3.28 (1.26–8.55) 0.015
Number of medicines, per unit increase 1.01 (0.91–1.12) 0.92
1 Multivariable mixed-effects logistic regression model adjusting for all covariates in the table and for GP-cluster as a random-effect
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Fig. 3 Significant enablers and barriers towards the willingness to deprescribe in a forest plot; Legend: Significant barriers and enablers towards
the willingness to deprescribe. Odds ratios from a multivariable mixed-effects logistic regression model adjusted for age, sex, education level,
number of medicines, living status, medication self management and GP as random-effect. OR sorted by point estimate (top-down); * from rPATD
Table 3 Answers to open questions on other enablers and barriers towards deprescribinga
Enablers Number of participantsa
side effects, interactions or no effect of medicines, feeling bad with medicine 37
trust in doctor to deprescribe when necessary 16
cost reduction 16
Barriers
feel well with current medicine, convinced that all are needed 56
fear of recurrent symptoms or worsening of health 45
trust in doctors to only prescribe what is necessary 25
a179 participants replied to both open-ended questions
bMore than one answer per patient possible
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comparison to many of the earlier studies in that we
only included participants with polypharmacy and multi-
morbidity. For example, the Australian study recruited
older adults taking one or more medicines and less than
half of their sample were taking 6 or more medicines
[30]. Eliciting the attitudes and beliefs of older adults
with polypharmacy is important because this is the
population that is most likely to benefit from deprescrib-
ing and it is possible that the views of this population
will differ. Older adults with polypharmacy may feel a
strong dependency towards their medicines, and also
might have established habits. It was interesting that in
the open-ended questions a commonly reported barrier
was the belief that all their medicines were necessary.
While we chose to only include participants with poly-
pharmacy, there have been inconsistent results in previ-
ous studies about the relationship between
polypharmacy and patient willingness to deprescribe. In
a Japanese study, a lower willingness to deprescribing in
a healthier and younger population was found, with a
higher willingness in older participants with more medi-
cines [22]. Similarly, in a US study having 2 or more
chronic medical conditions was found to be associated
with higher willingness to deprescribe, however age was
not associated [21].
Previous studies internationally have found contradict-
ory results as to whether or not number of medicines is
associated with willingness to deprescribing [19–22, 30].
We did not find an association between number of med-
icines and willingness to deprescribe in our population,
however, as we only included participants with polyphar-
macy, we are not able to determine if those on less med-
icines had different attitudes. Willingness to deprescribe
might be influenced by the individual’s perception of the
number of medicines that they take. Despite all our par-
ticipants having polypharmacy, only 54% felt that they
took a large number of medicines. Participants who
agreed that they take a large number or too many medi-
cines were more likely to be willing to deprescribe. This
is in line with a recent study in Switzerland, where pa-
tient perception of treatment burden differed signifi-
cantly from the doctor’s perception. For practice, it is
therefore important to find out the patient’s perceived
burden, so that discussion about deprescribing can be
accordingly targeted [31].
The only participant characteristic that we found to be
associated with willingness to deprescribe was higher
education. It may be that people who are more educated
are more open to change and critical of doctors’ advice.
Other baseline characteristics showed no association
with willingness to deprescribe similarly to studies in
Japan, Australia and USA [21, 22, 32].
The most important barriers from participant re-
sponses to our open questions were being convinced
that all their medicines are necessary and fear of recur-
rent symptoms. This is similar to the findings of a quali-
tative study in Switzerland among patients who did not
pursue deprescribing offers from their GP [33].
Implications
For the future, a good knowledge of barriers and en-
ablers from the patient view is important for developing
deprescribing interventions, guidelines, and patient and
clinician educational materials. Another important find-
ing of this study was that 81% would like to deprescribe
if new studies found harm from taking too many medi-
cines. This supports the need for further research into
the benefits and harms of deprescribing of different
medicines and in different populations. For guidelines
and patient and clinician educational materials, our re-
sults can be used to inform their content; older adults
with polypharmacy and multimorbidity want to be in-
formed about their medicines and to understand the rea-
sons for taking them. Talking about former bad
experiences and how potential negative outcomes of
deprescribing will be managed is important as this was
associated with reduced willingness to deprescribe. Fur-
thermore, asking about the subjective burden of medi-
cine intake in every patient, rather than looking at the
number of medicines taken regularly, could lead to more
success in deprescribing, since it was more associated
with the willingness to deprescribe while number of
medicines was not.
Clear instructions for participants how to cease certain
medicines will also be helpful. Overall, discussing the be-
liefs and attitudes of patients and determining if there
are any barriers towards deprescribing in the individual
will enhance shared decision making and support
deprescribing.
Limitations and strengths
In this study, the screening and recruitment was done by
GPs. Simple random sampling was not possible (many
Swiss GPs still have paper documentation) and so we
instructed the GPs to conduct consecutive sampling to
identify and recruit participants to reduce selection bias.
However, as this was external to the research team, we
cannot completely rule out the possibility of selection
bias by the GPs. Screening records from the GPs show
that 21% of participants were eligible during the screen-
ing period. This number is comparable to other Swiss
studies in ambulatory care on number of multimorbid
participants with polypharmacy [34]. Overall, men were
slightly overrepresented in our sample, but female par-
ticipants were significantly older with mean age of 79.8
years (SD 6) for women, compared to Swiss census data
[35]. It is also possible that patients who chose to par-
ticipate may have had more favorable views about
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deprescribing than those who refused (33% refusal rate).
Among our participants, 83 (28%) of participants re-
ported that they had less than three chronic conditions,
despite this being an inclusion criterion for screening
through GPs. As this likely indicates a problem with
how this data was collected (self-report according to a
pre-defined list), we were not able to use this variable
for analysis as intended a priori. Specifically, the under-
reporting of co-morbidities is likely due to our method
of checkboxes listing most prevalent chronic conditions
in patient-friendly language; participants might have had
conditions, which were not listed or might have known
their conditions by a different name. However, this likely
had little impact on our findings in regard to the results
representing the attitudes of those with multimorbidity
as it was the participants GP that determined their eligi-
bility based on this criteria. Another limitation is the
hypothetical and non-medicine specific nature of the
rPATD and additional questions used in this study. Add-
itionally, due to the cross-sectional nature of this study
we are not able to confirm directionality (i.e. cause and
effect) of the associations we identified between barriers
and enablers and willingness to deprescribe. Another
important limitation is that the non-rPATD additional
questions did not undergo any formal validation. The
two questions that were found to have the strongest as-
sociations with willingness to deprescribe (saying that
because they have a good relationship with their GP,
they would feel that deprescribing was safe and agreeing
that they would be willing to deprescribe if new studies
showed an avoidable risk) are both questions that were
created just for this study (not rPATD questions). As
they have not undergone validation (other than piloting
in four participants), these finding should be interpreted
with caution.
To our knowledge, this was the first study to use the
rPATD and other questions about barriers and enablers
towards deprescribing in a population most likely to
have potentially inappropriate medicines in Switzerland,
namely older adults with polypharmacy and multimor-
bidity. However, we do not know if our results are
generalizable to populations outside the German speak-
ing part of Switzerland, as we only used the German
translation of the rPATD (for pragmatic reasons). By
instructing GPs to recruit 5–6 eligible patients each we
aimed to maximize the distribution of participants from
across the German speaking part of Switzerland and pre-
vent bias that could have been created by a small num-
ber of GPs recruiting a large proportion of the
participants.
Conclusion
Most German speaking Swiss older adults with poly-
pharmacy are willing to deprescribe. GPs may be able to
increase deprescribing by building trust with their pa-
tients and communicating evidence about the risks of
medication use. Future research should explore how to
best engage patients in conversations about
deprescribing.
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